AlphAIAlphAI — Financial news for AI agents
investing.comSEP 242 min read$ACAD

Why is ACADIA Pharmaceuticals stock sliding today?

ACADIA Pharmaceuticals' stock fell 8.1% in pre-market trading after its Phase 2 trial for remlifanserin narrowly missed the primary endpoint, though it met a key secondary endpoint. The company will continue Phase 3 studies, removing the 30 mg dosage arm. CEO Catherine Owen Adams stated the data support the Phase 3 program. The stock is trading at $23.36, below its 52-week high of $30.96.

Original reporting
investing.com
Published Sep 24, 2026, 11:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ACAD
Bearish
high confidence
Mentioned
$ACAD
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ACADBearishHigh
01

Why it matters

The miss on the primary endpoint triggered an 8.1% pre‑market decline, highlighting the sensitivity of biotech stocks to trial outcomes.

02

Market read

The trial result is a primary catalyst for ACAD, influencing biotech sentiment and short‑term price action.

03

What to watch

Continuation of Phase 3 studies and removal of the 30 mg arm may preserve upside.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

ACADIA Pharmaceuticals announced topline Phase 2 results for remlifanserin in Alzheimer’s disease psychosis.

Company-level read

Ticker impact

$ACADBearishHigh confidence
Context

Phase 2 RADIANT trial missed primary endpoint, causing an 8.1% pre‑market drop.

Expected impact

downward pressure, potential further decline in intraday trading

Evidence & confidence

Investors priced in a clean readout; the miss on statistical significance drives sell‑off.

Market effects

Sector

Biotech sector may see broader risk‑off as trial failures raise concerns about Alzheimer’s pipeline.

Regional

US biotech stocks could face heightened volatility in early trading.

Global

Limited to investors tracking late‑stage CNS drug candidates.

Counterpoint

What could challenge this read

If the secondary endpoint holds clinical relevance, the stock could rebound on long‑term potential.

Key entities

  • Executive
    Catherine Owen Adams

    CEO of ACADIA, commented on trial continuation.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 25
$ACADMedAI 8/10

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

Acadia Pharmaceuticals (ACAD) stock fell 5% after analysts cut price targets following Phase 2 RADIANT trial results for Remlifanserin in Alzheimer's disease psychosis. The trial missed the primary endpoint but showed promise in a subgroup. Analysts from Needham, Deutsche Bank, BMO Capital, and Citizens lowered targets but maintained positive ratings, citing future potential.

stocktwits.com2 min
SEP 25
$ACADHighAI 8/10

ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%

ACADIA Pharmaceuticals (ACAD) shares fell 13% after Goldman Sachs initiated a 'sell' rating and $17 price target due to weak phase 2 trial results for remlifanserin. Citi and BMO Capital maintained positive ratings but lowered price targets. The company plans to present detailed results at an upcoming conference. Hedge funds increased holdings in Q2, with 38 funds holding positions.

finance.yahoo.com2 min
SEP 24
$ACADMedAI 8/10

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease…

ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) — Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develop

SEC EDGAR 8-K2 min
SEP 24
$ACADMedAI 8/10

BMO cuts Acadia Pharmaceuticals stock price target on trial miss

BMO Capital reduced its price target for Acadia Pharmaceuticals (ACAD) to $34, citing a trial miss, but maintained an Outperform rating. The stock is down 7.4% over the past week. The firm lowered the success probability for the drug candidate to 35% from 40%. Acadia generated $1.14 billion in revenue over the last twelve months and has a market cap of $3.93 billion.

investing.com2 min